Efficacy of combined androgen blockade therapy in patients with metastatic hormone‐sensitive prostate cancer stratified by tumor burden
- 25 January 2022
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 29 (5) , 398-405
Abstract
Objective: To determine the effect of combined androgen blockade with a first‐generation anti‐androgen on the prognoses of metastatic hormone‐sensitive prostate cancer patients stratified by tumor burden.Methods: We retrospectively analyzed the cases of metastatic hormone‐sensitive prostate cancer patients who were treated with androgen deprivation therapy in 2008–2017 at 30 institutions in Japan. To compare the overall survival and progression‐free survival rates of the patients treated with castration monotherapy and combined androgen blockade, we carried out a Cox proportional hazards regression analysis using both inverse probability of treatment weighting and instrumental variables methods. High‐burden disease was defined as the presence of four or more bone metastases and/or visceral metastasis.Results: Of 2048 patients, 702 (34.3%) and 1346 (65.7%) patients were classified as the low‐ and high‐burden groups, respectively. In each group, >80% of the patients were treated with combined androgen blockade. Although there was no significant between‐group difference in the overall survival according to the androgen deprivation therapy method, in the high‐burden group the progression‐free survival of the combined androgen blockade‐treated patients was significantly better than that of patients treated with castration monotherapy: inverse probability of treatment weighting method, hazard ratio 0.49, 95% confidence interval 0.34–0.71; instrumental variables method, hazard ratio 0.80, 95% confidence interval 0.60–0.98.Conclusion: In the high‐burden group, combined androgen blockade with a first‐generation anti‐androgen resulted in superior progression‐free survival compared with castration monotherapy. For well‐selected metastatic hormone‐sensitive prostate cancer patients, the use of combined androgen blockade might still have some suitable scenarios.Keywords
This publication has 25 references indexed in Scilit:
- Trans‐ P acific variation in outcomes for men treated with primary androgen‐deprivation therapy ( ADT ) for prostate cancerBJU International, 2015
- Recent Trends in the Initial Therapy for Newly Diagnosed Prostate Cancer in JapanJapanese Journal of Clinical Oncology, 2014
- Instrumental variable methods for causal inferenceStatistics in Medicine, 2014
- Contemporary Role of Androgen Deprivation Therapy for Prostate CancerEuropean Urology, 2012
- Combined androgen blockade with bicalutamide for advanced prostate cancerCancer, 2009
- Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modelingJournal of Health Economics, 2008
- Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice GuidelineJournal of Clinical Oncology, 2007
- Analysis of Observational Studies in the Presence of Treatment Selection BiasJAMA, 2007
- A re‐assessment of the role of combined androgen blockade for advanced prostate cancerBJU International, 2004
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsThe Lancet, 2000